Your browser is no longer supported. Please, upgrade your browser.
Settings
MRNS Marinus Pharmaceuticals, Inc. daily Stock Chart
MRNS [NASD]
Marinus Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.86 Insider Own1.14% Shs Outstand40.52M Perf Week-6.26%
Market Cap175.86M Forward P/E- EPS next Y-1.16 Insider Trans0.00% Shs Float40.07M Perf Month-24.39%
Income-31.40M PEG- EPS next Q-0.27 Inst Own74.80% Short Float8.90% Perf Quarter-24.65%
Sales- P/S- EPS this Y45.40% Inst Trans6.31% Short Ratio4.90 Perf Half Y-17.02%
Book/sh0.87 P/B4.99 EPS next Y-24.70% ROA-60.70% Target Price17.50 Perf Year-31.22%
Cash/sh0.98 P/C4.43 EPS next 5Y- ROE-65.60% 52W Range3.31 - 10.54 Perf YTD-46.81%
Dividend- P/FCF- EPS past 5Y-22.30% ROI- 52W High-58.35% Beta3.23
Dividend %- Quick Ratio5.90 Sales past 5Y- Gross Margin- 52W Low32.63% ATR0.45
Employees23 Current Ratio5.90 Sales Q/Q- Oper. Margin- RSI (14)27.58 Volatility8.59% 9.72%
OptionableYes Debt/Eq0.00 EPS Q/Q-89.00% Profit Margin- Rel Volume0.37 Prev Close4.34
ShortableYes LT Debt/Eq0.00 EarningsOct 30 Payout- Avg Volume728.44K Price4.39
Recom1.70 SMA20-11.08% SMA50-32.27% SMA200-26.66% Volume95,737 Change1.15%
Jul-02-18Initiated Cantor Fitzgerald Overweight $19
Mar-20-18Initiated Mizuho Buy $13
Feb-15-18Initiated H.C. Wainwright Buy $33
Dec-14-17Initiated Laidlaw Buy $18
Aug-10-16Reiterated Jefferies Buy $2.50 → $3
Jun-14-16Downgrade RBC Capital Mkts Outperform → Sector Perform
Mar-08-16Reiterated Stifel Buy $23 → $16
Dec-17-15Initiated RBC Capital Mkts Outperform $14
Nov-17-15Initiated Jefferies Buy $14
Oct-30-15Reiterated Oppenheimer Outperform $21 → $17
Aug-05-15Reiterated Oppenheimer Outperform $12 → $21
Nov-19-18 07:30AM  Marinus Pharmaceuticals to Present Ganaxolone Clinical Trial Data in CDKL5 Deficiency Disorder and PCDH19-Related Epilepsy at AES GlobeNewswire
Nov-16-18 11:56AM  Granite Point Capitals Returns, AUM, and Holdings Insider Monkey
Nov-06-18 08:37AM  Is the Options Market Predicting a Spike in Marinus Pharmaceuticals (MRNS) Stock? Zacks
07:30AM  Research Report Identifies Oil States International, Brightcove, Electronics for Imaging, Cirrus Logic, Innoviva, and Marinus Pharmaceuticals with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Oct-29-18 07:36AM  Marinus Pharmaceuticals: 3Q Earnings Snapshot Associated Press
07:30AM  Marinus Pharmaceuticals Provides Business Update and Third Quarter 2018 Financial Results GlobeNewswire
Oct-10-18 07:30AM  Marinus Pharmaceuticals Names Dr. Rolando Gutíerrez-Esteinou as VP of Clinical Development and Pharmacovigilance GlobeNewswire -13.32%
Oct-09-18 04:48PM  Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4) GlobeNewswire
Oct-05-18 04:00PM  Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire -10.82%
Sep-28-18 02:28PM  What Kind Of Shareholders Own Marinus Pharmaceuticals Inc (NASDAQ:MRNS)? Simply Wall St.
Sep-25-18 07:30AM  Marinus Completes Enrollment in its Magnolia Postpartum Depression Study GlobeNewswire
Sep-24-18 10:30AM  Deals Pile Up as Big Biotech Looks to Capitalize on the Growing Market ACCESSWIRE
Sep-20-18 04:05PM  Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Aug-30-18 04:15PM  Marinus Pharmaceuticals to Present at the Baird Healthcare Conference GlobeNewswire
Aug-28-18 07:30AM  Analysis: Positioning to Benefit within MannKind, Chimerix, Superior Energy Services, Marinus Pharmaceuticals, Airgain, and Eagle Pharmaceuticals Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Aug-09-18 10:15AM  7 Biotech Stocks With Big Upcoming Catalysts Kiplinger
Aug-07-18 07:30AM  Marinus Pharmaceuticals to Present at Wedbush/PacGrow Healthcare Conference GlobeNewswire
Aug-02-18 02:48PM  Here's Why Marinus Pharmaceuticals Inc. Fell as Much as 20.1% Today Motley Fool -13.02%
09:14AM  Marinus Pharmaceuticals: 2Q Earnings Snapshot Associated Press
07:30AM  Marinus Pharmaceuticals Provides Business Update and Second Quarter 2018 Financial Results GlobeNewswire
Jul-30-18 04:05PM  Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Jul-21-18 08:44AM  Canaccord Previews Biotech Catalysts In The Second Half: Neurological Drugs In Focus Benzinga
Jul-16-18 07:05AM  Free Technical Research on Marinus Pharma and Three More Biotech Equities ACCESSWIRE
Jul-12-18 12:54PM  Harry Boxers four health-care stocks to watch MarketWatch
Jul-11-18 10:52AM  Pfizer Doesn't Look Fundamentally or Technically Strong TheStreet.com
Jun-27-18 08:25AM  Analysis: Positioning to Benefit within Marinus Pharmaceuticals, Valley National, BB&T, Cognizant Technology Solutions, Cinemark, and International Game Technology Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Jun-21-18 07:30AM  Marinus Pharmaceuticals to Be Added to the Russell 2000 and Russell 3000 Index GlobeNewswire
Jun-19-18 07:30AM  Marinus Pharmaceuticals Initiates Pivotal Phase 3 Trial in Children with CDKL5 Deficiency Disorder GlobeNewswire
Jun-15-18 04:05PM  Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4) GlobeNewswire
07:55AM  Free Technical Reports on MannKind and Three Additional Biotech Equities ACCESSWIRE
Jun-06-18 03:43PM  Marinus Pharmaceuticals Has 3 Major Catalysts In 2018, Ladenburg Thalmann Says In Bullish Initiation Benzinga +14.09%
May-30-18 07:30AM  Marinus Pharmaceuticals to Present at Upcoming Investor Conferences GlobeNewswire +5.32%
May-29-18 07:30AM  Mayo Clinic-Backed NMTC Could Be Worth 3X This Year ACCESSWIRE
May-24-18 11:34AM  Here's Why Marinus Pharmaceuticals Rose as Much as 18.4% Today Motley Fool +15.11%
08:37AM  Benzinga's Daily Biotech Pulse: Eiger And Melinta Fall On Offerings, Apellis And Marinus Rise On Bullish Ratings Benzinga
May-14-18 07:30AM  Marinus Pharmaceuticals to Present at the UBS Global Healthcare Conference GlobeNewswire
May-11-18 08:25AM  Consolidated Research: 2018 Summary Expectations for STORE Capital, Microvision, International Game Technology, McKesson, Marinus Pharmaceuticals, and Alnylam Pharmaceuticals Fundamental Analysis, Key Performance Indications GlobeNewswire
May-02-18 09:33AM  Marinus Pharmaceuticals: 1Q Earnings Snapshot Associated Press +5.33%
07:30AM  Marinus Pharmaceuticals Provides Business Update and First Quarter 2018 Financial Results GlobeNewswire
Mar-08-18 07:30AM  Marinus Pharmaceuticals to Present at the Barclays Global Healthcare Conference GlobeNewswire
Mar-06-18 04:14PM  Biotech Jumps After Rival Pushes Back Depression Drug Tests Investor's Business Daily -13.71%
12:58PM  Here's Why Marinus Pharmaceuticals Dropped as Much as 17.7% Today Motley Fool
08:01AM  Marinus Pharma shares slide 14% premarket after company posts wider-than-expected loss MarketWatch
07:30AM  Marinus Pharmaceuticals Provides Business Update and 2017 Financial Results GlobeNewswire
Feb-23-18 02:13PM  Is There Now An Opportunity In Marinus Pharmaceuticals Inc (NASDAQ:MRNS)? Simply Wall St.
Feb-07-18 08:00AM  Report: Developing Opportunities within Discovery Communications, Otonomy, Marinus Pharmaceuticals, Citizens Financial Group, Washington Prime Group, and The Charles Schwab Future Expectations, Projections Moving into 2018 GlobeNewswire +5.64%
07:30AM  Marinus Pharmaceuticals to Attend Upcoming Investor Conferences GlobeNewswire
Jan-03-18 06:34AM  3 Best Healthcare Stocks of 2017 Motley Fool
Dec-28-17 09:01AM  Key Risks Facing Marinus Pharmaceuticals in December 2017 Market Realist +8.89%
07:32AM  How Do Marinus Pharmaceuticals Financials Look? Market Realist
Dec-27-17 12:45PM  Ganaxalone Faces Stiff Competition from Other Drugs under Development Market Realist
11:15AM  Why Ganaxalone Is a Promising Drug Candidate Market Realist
09:41AM  What Analysts Recommend for Marinus Pharmaceuticals in December Market Realist
Dec-21-17 07:58AM  [$$] Bain Makes Bank in Two Rebounding Biotechs Barrons.com
Dec-18-17 04:42PM  Why Mattel, Marinus Pharmaceuticals, and Northern Dynasty Minerals Slumped Today Motley Fool -9.70%
Dec-17-17 09:09AM  The 3 Best Biotech Stocks of 2017 Motley Fool
Dec-15-17 08:20AM  Todays Research Reports on Trending Tickers: ImmunoCellular Therapeutics and Marinus Pharmaceuticals ACCESSWIRE -15.43%
Dec-14-17 01:07PM  Here's Why Marinus Pharmaceuticals Is Soaring Today Motley Fool +15.47%
Dec-13-17 07:30AM  Marinus Pharmaceuticals Added to NASDAQ Biotechnology Index GlobeNewswire +9.63%
Dec-08-17 08:34AM  Why Marinus Pharmaceuticals Shares Spiked On Sage Therapeutics News Benzinga -9.03%
Dec-07-17 04:32PM  Here's Why Marinus Pharmaceuticals Rose as Much as 41.1% Thursday Motley Fool +39.58%
Nov-16-17 08:10AM  Market Trends Toward New Normal in Discovery Communications, Otonomy, Marinus Pharmaceuticals, Citizens Financial Group, Washington Prime Group, and Charles Schwab Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
Nov-10-17 08:10AM  Todays Research Reports on Stocks to Watch: Marinus Pharmaceuticals, Inc. and Otonomy, Inc. ACCESSWIRE
Nov-09-17 12:40PM  2 Antidepressant-Focused Biotech Stocks Are Surging Today. Here's Why. Motley Fool +14.14%
Oct-31-17 07:39AM  Marinus Pharmaceuticals posts 3Q loss Associated Press
07:30AM  Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2017 Financial Results GlobeNewswire
Oct-30-17 02:21PM  Are Marinus Pharmaceuticals Incs (MRNS) Interest Costs Too High? Simply Wall St. -5.34%
Sep-21-17 04:01PM  Marinus Pharmaceuticals to Present at the Cantor Fitzgerald Global Healthcare Conference GlobeNewswire
Sep-19-17 04:01PM  Marinus Pharmaceuticals Announces closing of Public Offering of Common Stock and full exercise of underwriters option to purchase additional shares GlobeNewswire
Sep-15-17 07:30AM  Marinus Pharmaceuticals Announces Pricing of Public Offering of Common Stock GlobeNewswire
Sep-14-17 04:01PM  Marinus Pharmaceuticals Announces Public Offering of Common Stock GlobeNewswire
Sep-12-17 11:42AM  Marinus Stock Surges on Successful Phase II Epilepsy Study Zacks -8.19%
08:10AM  Today's Research Reports on Stocks to Watch: Marinus Pharmaceuticals and Teva Pharmaceutical Industries ACCESSWIRE
Sep-11-17 10:35AM  Marinus Pharma Wins Big With Mid-Stage Epilepsy Study 24/7 Wall St. +33.01%
07:30AM  Marinus Announces Successful Clinical Trial Results and Declares CDKL5 Disorder Its Lead Pediatric Orphan Epilepsy Program for Ganaxolone GlobeNewswire
Aug-15-17 08:10AM  Today's Research Reports on Stocks to Watch: Marinus Pharmaceuticals and CEL-SCI Corporation ACCESSWIRE
Aug-03-17 08:10AM  Today's Research Reports on Stocks to Watch: Marinus Pharmaceuticals and Sparks Therapeutics ACCESSWIRE
Aug-01-17 09:32PM  Marinus Pharmaceuticals posts 2Q loss Associated Press
07:30AM  Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2017 Financial Results GlobeNewswire
Jun-30-17 10:57AM  Marinus' (MRNS) Ganaxolone Gets Orphan Drug Status in US Zacks -5.52%
08:00AM  Today's Research Reports on Stocks to Watch: Inpixon and Marinus Pharmaceuticals Accesswire
Jun-29-17 02:29PM  FDA Grants Orphan Drug Designation for Ganaxolone in CDKL5 Disorder GlobeNewswire
Jun-27-17 07:30AM  Marinus Pharmaceuticals Launches the Ganaxolone Clinical Program in Patients with Postpartum Depression GlobeNewswire
May-01-17 07:36AM  Marinus Pharmaceuticals posts 1Q loss Associated Press
07:30AM  Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2017 Financial Results GlobeNewswire
Apr-18-17 07:30AM  Marinus to present Ganaxolone DATA at American academy of neurology annual meeting GlobeNewswire
Apr-11-17 07:30AM  Dr. Lorianne K. Masuoka Joins Marinus Pharmaceuticals as Chief Medical Officer GlobeNewswire
Apr-10-17 07:30AM  Ganaxolone IV Clinical Data Presented at Leading International Status Epilepticus Medical Conference GlobeNewswire
Apr-05-17 09:00AM  Ligand Enters Commercial License and Supply Agreements with Marinus Pharmaceuticals for Captisol-Enabled Ganaxolone Business Wire
09:00AM  Ligand Enters Commercial License and Supply Agreements with Marinus Pharmaceuticals for Captisol-Enabled Ganaxolone
Mar-23-17 08:43AM  Ultragenyxs Seizure Drug Fails Study Investopedia
08:43AM  Ultragenyxs Seizure Drug Fails Study at Investopedia
Mar-22-17 04:16PM  MARINUS PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a +5.52%
Mar-16-17 01:04PM  MARINUS PHARMACEUTICALS INC Financials
Mar-15-17 07:30AM  Marinus Pharmaceuticals to Present at Oppenheimer Healthcare Conference GlobeNewswire
Mar-13-17 07:35AM  MARINUS PHARMACEUTICALS INC Files SEC form 10-K, Annual Report +8.97%
07:30AM  Marinus Pharmaceuticals Provides Business Update and 2016 Financial Results GlobeNewswire
Feb-14-17 07:30AM  Ganaxolone Reduces Seizures and Improves Behaviors in Angelman Syndrome Preclinical Model GlobeNewswire
Feb-01-17 04:07PM  MARINUS PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and E
07:30AM  Marinus Appoints Michael R. Dougherty to its Board of Directors GlobeNewswire
Marinus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical stage product candidate, ganaxolone, is an allosteric modulator of GABAA, developed in three different dose forms: intravenous (IV), capsule, and liquid. The multiple dose forms are intense to maximize the therapeutic range of ganaxolone for adults and pediatric patients. Ganaxolone acts as an anti-seizure, anti-anxiety, and anti-depressive actions; and acts on synaptic and extra synaptic GABAA receptors. The company is also developing ganaxolone for pediatric refractory epilepsy; postpartum depression; and acute epilepsy, which are in Phase II clinical study. In addition, it is developing ganaxolone IV formulation to treat status epilepticus. Marinus Pharmaceuticals, Inc. has a collaboration agreement with NovaMedica, LLC; and license agreements with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc. The company was founded in 2003 and is based in Radnor, Pennsylvania.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Smith Edward FCFOJan 29Sale7.913,00023,73049,800Jan 29 08:00 PM
Cashman Christopher MichaelCEOJan 18Sale6.289,56660,074247,903Jan 22 08:41 PM
Bain Capital Life Sciences Inv10% OwnerDec 19Sale7.43150,0001,114,6703,977,453Dec 19 08:30 PM
Bain Capital Life Sciences Inv10% OwnerDec 18Sale7.50300,0002,251,4404,127,453Dec 19 08:30 PM
Bain Capital Life Sciences Inv10% OwnerDec 15Sale8.10822,5476,658,6914,427,453Dec 19 08:30 PM